BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients

Loading news article.

BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients | WAPE

BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients

Article summary

Related companies

Comments —